Dallah Healthcare Co (SAU:4004) Research & Development: ﷼0 Mil (TTM As of Mar. 2026)


SAU:4004 Dallah Healthcare Co SAU:4004
92 GF Score
Price ﷼110.00
GF Value ﷼204.73
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is Dallah Healthcare Co Research & Development?

Dallah Healthcare Co SAU:4004 -0.90% 92 Research & Development is ﷼0 Mil as of Mar. 2026. GuruFocus rates SAU:4004 with a GF Score™ of 92/100 and a GF Value™ of ﷼204.73 (Possible Value Trap). The stock has 8 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Dallah Healthcare Co's Research & Development for the three months ended in Mar. 2026 was ﷼0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ﷼0 Mil.

Dallah Healthcare Co  (SAU:4004) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Dallah Healthcare Co Research & Development Related Terms

Dallah Healthcare Co Research & Development Historical Data

* Premium members only.

The historical data trend for Dallah Healthcare Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dallah Healthcare Co Research & Development Chart

Dallah Healthcare Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Dallah Healthcare Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
SAU:4004
92GF Score
Dallah Healthcare Co SAU:4004
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dallah Healthcare Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ﷼0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ﷼0 Mil mean?
Dallah Healthcare Co (SAU:4004) has a Research & Development of ﷼0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Dallah Healthcare Co and its competitors.
Is Dallah Healthcare Co's Research & Development too high?
Dallah Healthcare Co's current Research & Development is ﷼0 Mil. Overall, Dallah Healthcare Co has a GF Score™ of 92/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Dallah Healthcare Co's Research & Development compare to HCA and THC?
Dallah Healthcare Co's Research & Development of ﷼0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Dallah Healthcare Co and its competitors. Dallah Healthcare Co's current Research & Development is ﷼0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dallah Healthcare Co stock overvalued right now?
Based on GuruFocus' analysis, Dallah Healthcare Co (SAU:4004) is currently considered Possible Value Trap. The stock's GF Value™ is ﷼204.73, compared to a current price of ﷼110.00 — trading 46.3% below its estimated fair value. The current Research & Development is ﷼0 Mil. Dallah Healthcare Co's overall GF Score™ is 92/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Dallah Healthcare Co (SAU:4004), the current Research & Development is ﷼0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Dallah Healthcare Co (SAU:4004) Overvalued in 2026?

Based on GuruFocus' analysis, Dallah Healthcare Co stock appears to be undervalued. The current stock price of ﷼110.00 is trading 46.3% below its estimated GF Value™ of ﷼204.73. GuruFocus considers Dallah Healthcare Co to be Possible Value Trap.

Key valuation signals for SAU:4004:

  • Research & Development: ﷼0 Mil
  • GF Value™: ﷼204.73 vs. price of ﷼110.00 (46.3% below fair value)
  • GF Score™: 92/100 with 8 warning signs

No single metric tells the full story. See the SAU:4004 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Dallah Healthcare Co Business Description

Address 1157 King Fahad Road, Nakheel building, 2nd Floor, Riyadh, SAU, 12381
Dallah Healthcare Co provides and operates healthcare programs and utilities in the Kingdom of Saudi Arabia. The objectives of the company include operating, managing, and maintaining the healthcare entities, wholesale medicines, and retail of medical and surgical equipment, prosthetics, and devices for the disabled, hospital equipment, and manufacturing medicines, pharmaceuticals, herbals, health, cosmetics, detergents, disinfectants, and packaging in the Kingdom of Saudi Arabia. The reportable segments of the company are Medical Facilities and Pharmacies, and Distribution of Pharmaceutical Products. The company generates the majority of its revenue from the Medical Facilities and Pharmacies segment.
92GF Score

Get the complete analysis for SAU:4004

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

﷼110.00
Price
﷼204.73
GF Value